Drug Profile
Research programme: peripheral arterial disorders therapy - Integene International
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Integene International
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Peripheral arterial disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Peripheral-arterial-disorders in USA (Parenteral)
- 02 May 2014 Preclinical trials in Peripheral arterial disorders in USA (Parenteral)
- 02 May 2014 Integene International plans a phase I/II trial for Peripheral arterial disorders